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A functional serotonin transporter promoter polymorphism, HTTLPR, alters the risk of disease as well as brain
morphometry and function. Here, we show that HTTLPR is functionally triallelic. The LG allele, which is the L
allele with a common G substitution, creates a functional AP2 transcription-factor binding site. Expression assays
in 62 lymphoblastoid cell lines representing the six genotypes and in transfected raphe-derived cells showed co-
dominant allele action and low, nearly equivalent expression for the S and LG alleles, accounting for more variation
in HTT expression than previously recognized. The gain-of-function LALA genotype was approximately twice as
common in 169 whites with obsessive-compulsive disorder (OCD) than in 253 ethnically matched controls. We
performed a replication study in 175 trios consisting of probands with OCD and their parents. The LA allele was
twofold overtransmitted to the patients with OCD. The HTTLPR LALA genotype exerts a moderate (1.8-fold) effect
on risk of OCD, which crystallizes the evidence that the HTT gene has a role in OCD.
Received December 29, 2005; accepted for publication March 1, 2006; electronically published March 28, 2006.
Address for correspondence and reprints: Dr. David Goldman, Laboratory of Neurogenetics, National Institute on Alcohol Abuse and
Alcoholism, Rockville, MD 20852. E-mail: dgneuro@box-d.nih.gov
Am. J. Hum. Genet. 2006;78:815–826.  2006 by The American Society of Human Genetics. All rights reserved. 0002-9297/2006/7805-0009$15.00
The serotonin transporter strongly modulates serotonin
function and is a major therapeutic target in several psy-
chiatric diseases, including anxiety, depression, and
obsessive-compulsive disorder (OCD [MIM 164230]).
HTTLPR, a functional polymorphism of the 5′ flanking
region of the serotonin transporter gene (called HTT,
SLC6A4, or SERT),1 is an intensively studied locus.
More than 300 studies have investigated the role of
HTTLPR in diverse neuropsychiatric phenotypes.2 Re-
cently, HTTLPR was shown to determine the neuroan-
atomical size and functional coupling of the amygdala-
frontal cortical circuit that has been directly implicated
in a variety of psychiatric disorders, including OCD. The
focus of these imaging genetics studies was the S allele,
which leads to reduced gray matter volume in limbic
regions and disrupted amygdala-cingulate coupling after
emotional stimuli.3,4 Conversely, the gain-of-function L
allele had the opposite effect, an effect potentially rel-
evant to OCD for which hyperfrontality has been ob-
served in functional neuroimaging studies.5
HTTLPR has been considered functionally biallelic,
even though other genetic variations were known.
HTTLPR consists of varying numbers of copies of a 20–
23-bp imperfect repeat sequence. Among white individ-
uals, the frequency of the L allele (16 repeats) is ∼0.60,
and the frequency of the S allele (14 repeats) is ∼0.40.6
Substantial interpopulation variation occurs. Rare alleles
contain up to 20 copies of the repeat.7 Single-nucleotide
variants have been detected within HTTLPR,8 including
an ArG SNP that will be extensively discussed below.
However, none of these additional alleles was found to
be functional, although several (including the ArG SNP)
were tested in transfected mammalian cells. HTTLPR
was therefore treated as biallelic in linkage studies.
Concerning function, the S allele leads to lower ex-
pression of HTT mRNA and lower expression of se-
rotonin transporter in membranes.6,9 Furthermore, the
S allele appears to have a dominant mode of action,6,9
an observation that leads to the grouping of SS and SL
genotypes in many but not all linkage studies.10,11 In
studies in vivo, the L allele has been associated with
higher levels of HTT in platelets, postmortem brain,12
and living brain.12–14
Recently, an uncommon HTT variant, Val425,15
which leads to gain of function,16 was linked to severe
behavioral problems (treatment-resistant OCD, ano-
rexia nervosa, and Asperger syndrome) in two families.15
In particular, six patients with OCD in these families all
carried the Val425 allele.15 These results suggested that
the search for functional variation in HTT should be
extended and that gain-of-function variants might be
linked to OCD.
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Table 1
Primers and Probes for Two-Stage 5′-Exonuclease
Genotyping of HTTLPR Alleles
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Material and Methods
Human Subjects
Genomic DNA was extracted from 2,998 individuals, in-
cluding 624 African Americans (414 with drug addictions and
210 with no psychiatric diagnosis), 771 Finnish whites (480
with various psychiatric diagnoses and 291 with no psychiatric
disorders), 297 U.S. whites (group 1: 177 with various psy-
chiatric diagnoses and 120 with no psychiatric disorders), 286
U.S. whites (group 2: 154 with various psychiatric diagnoses
and 132 with no psychiatric disorders), 456 American Plains
Indians (a community-representative sample including 335 in-
dividuals with psychiatric diagnoses and 121 with no psychi-
atric diagnosis), and 564 Southwest Indians (a community-
representative sample including 359 with psychiatric disorders
and 205 with no psychiatric diagnosis). Allele and genotype
frequencies in the patients and controls in these populations
did not differ. Presumably, this is because of the clinical het-
erogeneity and the lack of any strong HTTLPR effect on risk
for the common but probably general diagnostic categories,
such as alcoholism and anxiety disorders. Therefore, overall
frequencies were computed. Human subjects were studied un-
der human research protocols approved by the Rutgers Uni-
versity School of Medicine, the National Institute on Alcohol
Abuse and Alcoholism (NIAAA), and the University of Hel-
sinki. All participants gave informed consent for genetic studies
on psychiatric disease. Subjects were interviewed for psychi-
atric traits with either the Structured Clinical Interview for
DSM-IV (SCID) or the Schedule for Affective Disorders and
Schizophrenia–Lifetime (SADS-L), and diagnoses were made
according to DSM-IIIR criteria.
NIMH OCD Case-Control Study
Under a human research protocol approved by the National
Institute of Mental Health (NIMH) Institutional Review Board
(IRB), 169 patients with OCD and 253 controls without psy-
chiatric disorders were ascertained at the NIMH. All partici-
pants gave informed consent. All participants were interviewed
with the SCID, and diagnoses were made using DSM-IIIR cri-
teria. The OCD sample was white and consisted of 97 males
and 72 females, with an average age of 41.7 years. The control
sample included 137 males and 116 females, with an average
age of 39.9 years.
Toronto OCD Study of Parents-Child Trios
A total of 581 individuals were ascertained, including 175
OCD-affected child-parents trios, at the Centre for Addiction
and Mental Health, Toronto, under a human research protocol
approved by that institution’s IRB. All participants gave in-
formed consent. Probands were recruited from consecutive re-
ferrals to the Anxiety Disorders Clinic. All participants were
assessed using the SCID and the Yale-Brown Obsessive Com-
pulsive Scale17 by trained interviewers. All information ob-
tained was reviewed by a psychiatrist (M.A.R.) experienced in
the diagnosis and treatment of OCD and related conditions,
to insure diagnostic accuracy in using DSM-IV criteria. Only
probands with confirmed OCD were included. Exclusion cri-
teria included lifetime history of neurological or metabolic dis-
ease, bipolar disorder, psychotic disorder, or substance depen-
dence. The transmission/disequilibrium test (TDT) was
performed using complete parents-child trios and without re-
gard for the affection status of parents. The TDT sample in-
cluded 556 whites, 11 Hispanics, and 14 Asians. The probands
comprised 69 males and 96 females, with an average age of
38.2 years. There were a total of 86 transmissions from het-
erozygous parents.
Two-Stage 5′-Nuclease Genotyping of HTTLPR, Including
S, LA, and LG Alleles
Oligonucleotide primers and dye-labeled probes were de-
signed to optimize allele discrimination by use of Primer Ex-
press software (Applied Biosystems). The L amplicon was 182
bp, and the S amplicon was 138 bp. Genotyping was accom-
plished in two stages. Stage 1 distinguished S from L alleles.
Stage 2 distinguished LA from LG alleles. We used a total of
four fluorogenic probes, two probes for each stage. For stage
1, the allele-discriminating probe (ADP) was capable of hy-
bridizing once, and once only, to the 43-bp L insertion, and
an internal control probe (ICP) hybridized to a sequence lo-
cated within the same amplicon but specific to a divergent
repeat found only once in the amplicon and not involved in
the insertion/deletion. For stage 2, probes were designed that
were specific to the LA and LG alleles. The fluorogenic probes
were labeled at the 5′ end with either FAM or VIC (table 1).
PCR was performed in a 25-ml volume, with 25–50 ng DNA,
120 nM ADP, 80 nM ICP, PCR primers (100 nM of each),
dimethyl sulfoxide (DMSO) (4% by volume), and 1#Master
Mix (ABI). Amplification conditions were 2 min at 50C, 10
min at 95C, and then 40 cycles at 96C for 15 s and at 62.5C
for 90 s. Genotypes were generated using ABI PRISM 7700
Sequence Detection system software. Stage 1 and stage 2 ge-
notypes were combined to assign samples to one of six ge-
notypes: SS, SLA, SLG, LALA, LALG, and LGLG. On each plate,
previously sequenced standards were introduced. Stage 1 stan-
dards were SS, LS, and LL, and stage 2 standards were LALA,
LALG, and LGLG.
To evaluate genotyping accuracy, one-quarter of the sam-
ples, randomly selected, were genotyped in duplicate. The error
rate was !0.005, and the completion rate was 10.95.
Resequencing
Genomic DNA was extracted from 106 lymphoblastoid cell
lines derived from U.S. white controls. A 528-bp amplification
product containing the entire HTTLPR region (L allele) was
generated using a “touch-down” PCR procedure. Reaction
mixtures contained 100 ng of genomic DNA; 0.2 mM each of
dATP, dCTP, and dTTP; 0.1 mM dGTP; 0.1 mM 7-deaza-2′-
dGTP; 0.4 mM of each primer; 10 mM Tris (pH 8.3); 50 mM
KCl; 1.5 mM MgCl2; 4% DMSO; and 1 U Taq DNA poly-
merase in a final volume of 25 ml. The reference sequence used
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Figure 1 A, Schematic of HTTLPR alleles. An ArG substitution (boxed letter) is located at nucleotide 6 within the first of two extra
22-bp repeats that characterize the L allele, located 1,629 nt 5′ of exon 1 of HTT.8 This position corresponds to nucleotide 168 of the reference
sequence (NCBI accession number AF126506). B, The LG allele creates an AP2-DNA binding site. The autoradiograph shows the presence of
a specific AP2 DNA-protein complex in nuclear extracts from JEG-3 cells. The gel-shift assay used 33P-labeled LG double-stranded oligonucleotide
probe (G). Addition of unlabeled competitor DNA (G) or an AP2 consensus sequence (AP2) resulted in disappearance of the specific band.
Neither the LA competitor DNA (A) nor the SP1 competitor DNA (SP1) displaced LG-specific binding. C, A specific DNA-protein complex was
not seen with the LA double-stranded oligonucleotide probe. D, “Supershift” gel-shift assay. A combination of 5 mg anti-AP2 antibody and 5
mg recombinant AP2 further retarded the migration of the LG-specific DNA-protein complex, as shown by the arrow indicating the supershift
band. No supershift was seen with antibody to the NF1 transcription factor. 33P-labeled AP2 probe served as a reference.
to determine the genomic nucleotide positions and to design
primers was National Center for Biotechnology Information
(NCBI) accession number AF126506. The forward primer was
5′-GGCGTTGCCGCTCTGAATGC-3′, and the reverse primer
was 5′-GAGGGACTGAGCTGGACAACCAC-3′. DNA was
denatured at 95C for 5 min. Annealing was at 63C for 30
s for the first 2 cycles, at 62C for 30 s for the next 2 cycles,
and at 61C for 30 s for another 36 cycles. Extension was
consistently performed at 72C for 1 min. PCR was terminated
by extension at 72C for 10 min. The products were purified
using the MiniElute PCR Purification Kit (QIAGEN). Primers
for bidirectional sequencing were the same as those used for
PCR as described above. The 10-ml sequencing reaction mix-
ture contained 4 ml BigDye Terminator RR Mix (ABI), 2.84
ml dH2O, 1.6 pmol of forward or reverse primer, and 3 ml of
purified HTTLPR PCR amplicon. Cycle conditions for se-
quencing were 25 cycles consisting of denaturation at 96C
for 10 s, annealing at 50C for 5 s, and extension at 60C for
4 min. Sequencing reaction products were purified using Per-
forma DTR (Edge BioSystems) columns, were dried, were di-
luted with 25% formamide (v/v), were denatured at 95C for
5 min, and were analyzed on a 3100 Genetic Analyzer (ABI).
HTT Expression in Lymphoblastoid Cell Lines
HTT mRNA expression was measured in 62 lymphoblastoid
cell lines derived from Finnish whites collected at the University
of Helsinki as described above in “Human Subjects.” The 62
cell lines were from 30 males and 32 females, with an average
age of 37.6 years. Donors included individuals with various
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Figure 2 A, Sequence and organization of HTTLPR repeats.
Sequences from 1797 to 1268 relative to the HTT transcription
start site are shown. This segment, encompassing the HTTLPR region,
was inserted into the pGL4.10 expression plasmid. PCR primers used
for genomic amplification are indicated in underlined lower-case let-
ters. AP2 sites are boxed. Capital letters indicate the 43-bp insertion
containing the ArG SNP, which is in brackets. Previously, this region
was considered to be a 44-bp insertion/deletion, because of an addi-
tional C in the reference sequence (NCBI accession number AF116506).
This region of sequence disparity is shown in bold letters (five Cs).
Our sequencing results (106 samples) and those of Nakamura et al.8
and Kraft et al.18 confirm the sequence presented. A rare substitution
within this region (CrT; frequency 0.0048 in present study and 0.007
in study by Nakamura et al.) is underlined. B, HTTLPR LA and LG
alleles detected by direct sequencing. Representative electrophero-
grams show the position of the ArG SNP (arrows).
psychiatric diagnoses; the most frequent were alcoholism, an-
tisocial personality disorder, depression, and anxiety disorders.
However, cell lines were selected for expression studies on the
basis of genotype alone, because of substantial preexisting evi-
dence that HTTLPR influences behavior and the vulnerability
to psychiatric disease. Cells were cultured in 15-cm2 flasks with
4 ml RPMI (Roswell Park Memorial Institute medium) con-
taining 25% fetal bovine serum, 2% 200-mM glutamine, and
1% gentamicin (5 mg/ml) at 37C, with 5% CO2. After 48 h,
100 mM forskolin was added, and cell culture was terminated
after 72 h.
Total RNA Extraction
Cells were harvested by centrifugation at 2,300 rpm for 3
min at 4C. Pellets were homogenized in 0.75 ml TRIzol (In-
vitrogen). Samples were incubated at room temperature for 5
min, were shaken vigorously for 1 min after 0.2 ml of chlo-
roform was added, were held at room temperature for another
2.5 min, and then were incubated at 80C for at least 1 h.
The supernatant was transferred to 1.2-ml microfuge tubes
(0.5 ml/tube) after centrifugation at 4,000 rpm for 15 min at
4C, and a 53% volume of 100% ethanol was added. Then,
samples were applied to RNeasy minicolumns (QIAGEN), and
the manufacturer’s protocol was followed. Total RNA con-
centration was measured spectrophotometrically, and samples
were stored at 80C for no more than 1 wk.
Quantitation of HTT by Real-Time PCR
One mg of total RNA was used to synthesize first-strand
cDNA by use of the Cloned AMV First-Strand Synthesis Kit
(Invitrogen) and the manufacturer’s protocol. HTT mRNA
was measured on an ABI PRISM 7700 Sequence Detection
System. Primers and probes were designed on the basis of
NCBI SLC6A4 cDNA reference sequence NM_001045. The
forward primer was 5′-GAAACCCAATTGGCAGAAACTC-
3′, and the reverse primer was 5′-GAAGATCTGAGCGGCTG-
CAT-3′. The intron-spanning probe was 6FAM-ATCCACAC-
CCCTGTCT-MGBNGQ. The endogenous reference was 18S
rRNA (ABI). The 25-ml real-time PCR volume included 12.5
ml TaqMan Universal PCR Master Mix, 1.25 ml of 20# HTT
mix, 1.25 ml of 20# 18S mix, 2 ml of products from the first-
strand cDNA synthesis, and 8 ml RNase-free water. The ther-
mal cycling conditions were 40 cycles at 95C for 15 s and at
60C for 1 min. Amplification was followed by a hold at 50C
for 2 min and at 95C for 10 min. HTT mRNA concentration
was estimated by the difference between HTT Ct (the ampli-
fication cycle at which the signal exceeded the background)
and 18S Ct, which yields an HTT:18S rRNA ratio and a rel-
ative HTT concentration, by use of the equation 2DDCt, be-
cause per-cycle amplification efficiency was almost equal to
100%. Each of the 62 cell lines was assayed in quadruplicate.
Gel-Shift Assays
Nuclear extracts containing AP2 were prepared from JEG-
3 cells (GENEKA Biotechnology) and were stored at 80C.
For “supershift” experiments, recombinant AP2 (Promega)
was used. Single-stranded, complementary, 26-bp oligonucle-
otide sequences corresponding to the HTTLPR LA and LG allele
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Figure 3 Effect of HTTLPR S, LA, and LG alleles on HTT-specific
mRNA expression in lymphoblastoid cell lines. Cell lines with geno-
types SS ( ), SLA ( ), SLG ( ), LALA ( ), LALGnp 12 np 15 np 7 np 12
( ), and LGLG ( ) were identified. Mean HTT mRNA ex-np 9 np 7
pression values were measured by real-time PCR in triplicate cultures
and were normalized to 18S rRNA levels, as described in the “Material
and Methods” section.
Table 2





SS SLA SLG LALA LALG LGLG S LA LG
Finnish whites 771 .15 .44 .08 .24 .09 .01 .40 .51 .09
U.S. whites group 1 297 .16 .33 .09 .26 .14 .03 .37 .49 .14
U.S. whites group 2 286 .12 .37 .08 .22 .18 .02 .35 .50 .15
Plains Indians 456 .42 .47 .01 .09 .01 .00 .66 .33 .01
Southwest Indians 564 .42 .43 .01 .13 .01 .00 .64 .35 .01
African Americans 624 .07 .25 .12 .27 .23 .06 .25 .51 .24
AP2-binding motifs were annealed to form double-stranded
probes. For the LA allele, the oligonucleotide was 5
′-gatcgaaca-
cCCCCCaGCAggcccgt-3′ (the upper strand, with the binding
site in capital letters and the LA allele shown as a lower-case
“a” within the binding site). For the LG allele, the oligonucle-
otide was 5′-gatcgaacacCCCCCgGCAggcccgt-3′ (with the LG
allele shown as a lower-case “g” within the binding site). The
“consensus” AP2 oligonucleotide was 5′-gatcgaactgaccGCCC-
GCGGCccgt-3′ (Promega) and was based on the consensus
AP2-binding site (5′-GCCNNNGGC-3′). The AP2 antibody for
the “supershift” assay was from GENEKA Biotechnology. [g-
33P]-ATP (Perkin-Elmer Life Science) probes for gel-shift assays
were generated by labeling double-stranded oligonucleotides
with T4 polynucleotide kinase (Promega) after annealing the
complementary oligonucleotide and purifying it through a Bio-
Spin 30 chromatography column (Bio-Rad). Binding assays
were performed for 20 min at room temperature by use of 2
ml nuclear extract (10 mg total protein) in 15-ml reactions con-
taining binding buffer (10 mM HEPES [N-2-hydroxyethyl-
piperazine-N′-2-ethanesulfonic acid; pH 7.8], 50 mM KCl, 5
mM MgCl2, 1 mM EDTA, and 5% glycerol), 1 mM dithio-
threitol, 0.25 mg poly[dI:dC], and 0.2 ml radiolabeled probe
(1.75 pmol; 100,000 cpm/ml). In competition experiments, un-
labeled competitor (50# molar excess) was included with the
nuclear extract for 10 min before the addition of labeled probe.
In the “supershift” experiments, specific antibody was incu-
bated with AP2 for 25 min at room temperature, after probe
addition. Complexes were separated on a Novex 6% DNA
retardation gel (0.5# Tris-borate-EDTA) at 300 V for 16 min
at room temperature. Gels were dried and exposed to x-ray
film for 12 h.
Luciferase Reporter Constructs, Transfection, and Expression
Assays
Genomic DNA samples with S, LG, or LA alleles were selected
for PCR-based cloning of HTTLPR. PCR primers and con-
ditions were the same as for resequencing. The PCR products
(529 bp for LG and LA; 486 bp for S) were cloned into pCR-
TOPO vector (Invitrogen) and then were subcloned into
pGL4.10 (Promega) by standard molecular techniques. Se-
quences of inserts were confirmed by direct sequence analysis
using M13 forward and reverse primers. The RN46A raphe-
derived cell line was generously provided by Scott R. Whitte-
more (University of Louisville School of Medicine) and was
maintained in Dulbecco’s modified Eagle medium (DMEM)
and Ham’s F12 (1:1 v/v) with 5% fetal calf serum at 33C in
a humidified incubator (95% air, 5% CO2). RN46A cells were
seeded at a density of cells per well into a 12-well52# 10
tissue-culture plate. When the cells were 90% confluent, the
HTTLPR-pGL4.10 (firefly luciferase) and pRL-SV40 (Renilla
luciferase) constructs were cotransfected using Lipofectamine
2000 (Invitrogen). For AP2 transcription-factor competition
experiments, a double-stranded decoy DNA was also cotrans-
fected. Sequences used to prepare the LG and LA decoy DNAs
were identical to those used for gel-shift assay probes. The
cells were harvested for the Dual-Luciferase Reporter Assay
System (Promega) by passive lysis buffer 24 h after transfec-
tion. The activities of both firefly luciferase and Renilla lucif-
erase were quantified as relative light units (RLU). Each of the
three HTTLPR-pGL4.10 constructs or an empty pGL4.10
plasmid was transfected in triplicate. The ratio of firefly RLU
to Renilla RLU in a sample from each well was determined,
and the values were normalized to the S allele.
Data Analysis
HTT allele and genotype expression values were computed
by multiple regression using data from 62 lymphoblastoid cell
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Figure 4 Relative HTT mRNA levels in 62 human lympho-
blastoid cell lines with HTTLPR genotypes SS ( ), SL ( ),np 12 np 22
and LL ( ), before and after treatment with 100 mM forskolin.np 28
Table 3
P Values for Significance of Effects of HTTLPR




SLG LGLG LALG SLA LALA
SS … … .034 .00007 .000002
SLG … … … .0157
LGLG … .012 .0009
LALG … .009
SLA …
NOTE.—Results are for HTT mRNA expression in 62
lymphoblastoid cell lines as shown in figure 3.
lines (7–15 cell lines per genotype). Genotype-specific expres-
sion was estimated assuming codominance (i.e., additive effects
of alleles in a genotype). To test for dominance and/or reces-
sivity, these predicted genotype expression values were com-
pared, by linear regression, with the expression observed in
the cell lines. Analysis of variance was used to calculate ge-
notype-attributable variance.
Association with OCD was evaluated using x2 and logistic
regression analyses. First, association was tested using the in-
formation that LA is a high-expressing allele and by combining
the S and LG alleles, which are low and closely equivalent in
expression. Thus, there were again three genotypes. Second,
linkage was evaluated using HTT expression scores predicted
by genotype.
Results
Single-Nucleotide Variants in HTTLPR
A common single-base substitution (ArG) occurs at
the sixth nucleotide within the first of two extra 20–23-
bp repeats in the L allele (fig. 1). The two L alleles LA
and LG, together with the S allele, comprise a triallelic
locus. The ArG substitution is located 1,629 bp up-
stream of the transcription start site (fig. 2A) and was
genotyped in the second step of a two-stage 5′-nuclease
assay for the triallelic locus. LG corresponds to 1 of 10
SNPs detected within HTTLPR by Nakamura et al.8 (fig.
2A and 2B). The alleles corresponding to LA and LG were
designated “z” and “m” by those investigators. In several
populations, all three alleles are abundant or highly
abundant, as will be described below. Other novel al-
leles detected by Nakamura et al.8 were rare, and we
did not observe them, even though we resequenced the
HTTLPR region in 106 clinically and ethnically diverse
individuals.
HTTLPR Allele and Genotype Distributions
in Populations
Using a two-stage 5′-nuclease assay, we determined
triallelic HTTLPR genotypes and allele frequencies in
five populations, comprising 2,998 total individuals: 624
African Americans, 771 Finnish whites, 583 U.S. whites,
456 Plains Indians, and 564 Southwest Indians. The
Southwest Indians, Plains Indians, and Finnish whites
are populations that are relatively nonadmixed. The fre-
quency of S was lowest in individuals of African descent
(0.25), was intermediate in whites (0.35–0.40), and was
highest in American Indians (0.64–0.66). The S:LA:LG
ratio was 4:5:1 in whites, 2.5:5:2.5 in African Amer-
icans, and 2:1:0 in American Indians (i.e., the LG allele
was nearly absent in both American Indian populations)
(table 2).
HTTLPR Genotype–Attributable Variance
To estimate the proportion of variance in HTT ex-
pression that is attributable to HTTLPR in natural pop-
ulations, simulation analyses were performed with an N
of 100,000 to represent various populations. Genotypes
were assigned on the basis of allele frequencies (e.g.,
frequency of the LGLG genotype was set at 0.0001 in
American Indians but at 0.0586 in African Americans).
Expression values were randomly assigned for each in-
dividual on the basis of genotype, expression value of
each genotype, and SD of genotype-specific expression.
Genotype-attributable variance was then recalculated.
With knowledge of S and L alleles alone, genotype-
attributable variance was 0.22 in whites, 0.09 in African
Americans, and 0.44 in American Indians. In American
Indians, the LG allele is rare. Knowledge of the LG allele
substantially improved prediction of HTT expression in
other populations, increasing to 0.30 in whites, 0.25 in
African Americans, and 0.45 in American Indians.
Creation of an AP2 Site by the LG Allele
The LG allele creates a potential binding site for tran-
scription factor AP2 (fig. 1A). These nucleotides are ab-
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Figure 5 Codominance of HTT mRNA expression. The codom-
inance of HTT mRNA expression normalized to 18S mRNA was ob-
served in 62 lymphoblastoid cell lines representing the six HTTLPR
genotypes. Expression values represent the means of 7–15 cell lines
per genotype. Observed expression is plotted versus the expression
expected on the basis of the codominant model and of computed allele-
expression values: 0.50 for S, 0.57 for LA, and 1.16 for LG. For observed
vs. expected, and .rp 0.84 Pp .038
Figure 6 Relative HTT mRNA levels in lymphoblastoid cell lines
with various intron 2 VNTR genotypes.
sent in the S allele. To determine whether AP2 binds to
LA or LG, we performed gel-shift assays, using nuclear
extracts enriched for AP2, prepared from JEG-3 cells.
Only the LG double-stranded oligonucleotide specifically
bound AP2 (fig. 1B and 1C). AP2 was part of the pro-
tein-DNA complex, as confirmed by a gel “supershift”
experiment using an antibody specific to AP2 (fig. 1D).
Quantitation of HTT mRNA Levels by Real-Time PCR
HTTLPR predicts HTT expression in lymphoblasts,
reporter constructs,6 and antemortem14 and postmor-
tem12 human brain. We found that HTT mRNA levels
varied across the six HTTLPR genotypes in 62 lym-
phoblastoid cell lines (figs. 3 and 4). The lowest-ex-
pressing genotype was SS, whereas LALA was the highest
expressing, differing significantly from each of the five
genotypes other than SLA (fig. 3 and table 3). The nor-
malized (to SS genotype) expression value of each allele
was calculated using all the data, and these values were
0.50 for the S allele, 0.57 for the LG allele, and 1.16 for
the LA allele.
The HTTLPR alleles are codominant in action, as
shown in figure 5, in which the expression value ex-
pected (on the basis of codominance) for each genotype
is plotted versus the observed level. Expression was pre-
dicted by the codominant model ( ). In addition,rp 0.84
the two heterozygous genotypes that contain one copy
of the S allele did not exhibit lower-than-expected ex-
pression, as predicted by the S-dominant model.
Residual variation in HTT expression that is visible
within each genotype group may be attributable to a
second polymorphism at HTT or elsewhere. A potential
origin is an intron 2 17-bp VNTR.19 However, the mean
levels of relative HTT mRNA for the VNTR genotypes
were for genotype 9/10, for2.81 1.29 3.23 0.81
10/10, for 10/12, and for 12/2.88 0.40 2.53 0.33
12 ( ) in the 62 lymphoblastoid cell lines (fig. 6).P 1 .46
These findings are consistent with a previous report.19
Functional Equivalence of LG and S in Transfected
Cells
We introduced HTTLPR-luciferase plasmids (HTTLPR-
pGL4.10) into RN46A cells derived from rat dorsal ra-
phe neurons20 and determined the effect of each allele
on basal transcription. The 2.8-fold difference produced
by the S and LA allele constructs is similar to the allele-
specific effect seen by Mortensen et al.,21 who used a
different and larger reporter construct but the same re-
cipient cell line. Under basal conditions, the LG construct
had half the relative luciferase activity as did the LA allele
(fig. 7A). The S and LG constructs did not differ in bas-
al expression. All three reporter constructs were equal-
ly activated by 50 mM forskolin, indicating that the
HTTLPR region was activated normally (fig. 7A).
Equalizing of LA- and LG-Driven Transcription
by an LG-Based “Decoy” DNA
LG had reduced transcriptional efficiency relative to
that of LA and LG, as a result of the creation of an AP2-
binding site. Therefore, we tested whether this AP2 site
acts as a transcriptional suppressor. We depleted cells
of AP2 by introducing into RN46A cells carrying S, G,
or A allele constructs a double-stranded DNA “decoy”
containing the AP2-binding sequence from the LG allele
(Oligo-G). A decoy DNA having the same sequence but
carrying the LA allele (Oligo-A) was used for compari-
son. Twenty-four hours after transfection, luciferase ac-
tivity was measured. The Oligo-G treatment equalized
LG and LA allele reporter expression (fig. 7B), whereas
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Figure 7 Reduction of basal HTTLPR transcriptional activity by the LG allele relative to the LA allele. A, Effect of three HTTLPR alleles
on reporter transcription. RN46A cells were transfected with HTTLPR-luciferase plasmids (pGL4.10). The effect of each allele on basal
transcription was measured as relative luciferase level (ratio of firefly luciferase to Renilla luciferase) and was normalized to basal S allele
expression. There was no statistically significant difference between S and LG. However, LA was significantly different from both S and LG
( ). Transfected cells carrying each of the three different reporter plasmids and treated with 50 mM forskolin showed an approximatelyP ! .01
twofold increase in relative luciferase level, compared with the basal condition. B, Effect of an LG decoy on expression of three HTTLPR
reporters. The double-stranded LG-specific decoy DNA (Oligo-G) containing the AP2-binding sequence was transfected into RN46A cells carrying
the S, LG, or LA allele in HTTLPR-pGL4.10 reporter plasmids. An LA-specific decoy DNA (Oligo-A) was used for the control. Twenty-four
hours after transfection, luciferase activity was measured and normalized for transfection efficiency. Results are presented relative to expression
determined for Oligo-A–treated cells carrying the S allele reporter plasmid. Treatment with Oligo-G decoy DNA equalized LG and LA allele
reporter expression, whereas the control decoy DNA had little effect (compare basal expression in panel A with expression of Oligo-A–treated
cells in panel B).
the Oligo-A decoy DNA had little effect (compare basal
expression in panel A with expression of Oligo-A–
treated cells in panel B in fig. 7).
Linkage of Gain-of-Function HTTLPR Genotype
to OCD in Case-Control Sample
HTTLPR genotype and allele frequencies were com-
pared in 169 patients with OCD and 253 controls. The
higher expressing LA allele was associated with OCD
( ; ) (table 4). We also took advantage2x p 6.64 Pp .036
of knowledge of HTTLPR allele function, grouping the
LG and S alleles—which are low and closely equivalent
in expression—and comparing them with the high-ex-
pressing LA allele ( for allele-based associationP ! .021
with OCD). Patients with OCD were twice as likely to
have the highest-expressing genotype LALA (table 4). Fi-
nally, linkage was performed using genotype-predicted
expression scores. The mean (SD) predicted expres-
sion score in patients with OCD was higher than in
controls ( vs. ; , by2.76 0.80 2.59 0.59 Pp .024
two-tailed test).
Replication of Linkage in TDT Data Set
TDT analysis of 86 informative OCD-affected child-
parents trios derived from 175 pedigrees (total Np
) in the Toronto OCD Study revealed that the LA581
allele was twofold overtransmitted relative to the lower-
expressing alleles (S and LG) ( ). The strongestP ! .023
result was again obtained after function-based grouping
of the S and LG alleles ( ) (table 5).Pp .010
Discussion
The HTTLPR promoter polymorphism is linked to be-
havior. However, there are many contradictory findings,
and the bulk of the findings involve the loss-of-function
S allele. Contradictions arise from differences in source
populations, methods of phenotypic assessment, and
chance. In some studies, ethnic variation could mask or
create associations. In our study, it is unlikely that the
linkages of OCD to the gain-of-function allele and ge-
notypes are biased by population stratification, because
TDT allele-based linkage in complete parents-child trios
is invulnerable to these effects22 and because, in the case-
control study, all subjects were white.
Our results point to an important additional origin of
variability—namely, unrecognized functional allelic var-
iation. Because LG drives expression nearly equivalently
as S, studies that include many LG alleles within SL and
LL genotypes may underestimate the effect of HTTLPR.
LG creates a binding site for AP2, one of many nuclear
factors that function as transcriptional activators or re-
pressors.23–26 This is based on three lines of evidence:
basal mRNA levels in lymphoblasts, allele-specific ex-
pression in the transfected neuronal cell line, and the
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Table 4
























SS, SLG, LGLG .25 .26





NOTE.—The HTTLPR LA (high expressing) allele is
more abundant in OCD cases, as is the LALA (most
highly expressing) genotype. Because LG and S alleles
are closely equivalent in HTT expression, these alleles
were grouped and were compared with the LA allele,
also revealing significant genotype-based and allele-
based linkage.
a (5 df); .2x p 24.7 Pp .0001
b (2 df); .2x p 6.69 Pp .035
c (2 df); .2x p 13.6 Pp .0011
d (1 df); .2x p 5.32 Pp .021
Table 5






S LG LA S, LG LA
Transmitted 27 11 48 20 41
Untransmitted 44 16 26 41 20
NOTE.—Results are from 86 informative parents-
child trios derived from 175 pedigrees. Triallelic
analysis ; low/high analysis .Pp .023 Pp .010
a The low/high analysis grouped the S and LG
alleles because they have low and nearly equivalent
effect on HTT expression.
AP2 decoy-DNA effect in transfected cells, with the LG-
specific AP2 site acting as a suppressor. However, this is
not the only AP2 site within HTTLPR. The S and LA
reporter constructs also respond to AP2 decoy DNA (fig.
7B). Nonetheless, the responses for those constructs
were weaker than those for the LG construct. A second,
untested AP2 site is predicted in all three alleles, located
135 bp 3′ of the 43-bp insertion that creates the L allele.
Nakamura et al.8 tested the function of the LA and LG
alleles, also transfecting them into RN46A cells. In their
hands, the z and m alleles (as they designated them) were
indistinguishable, although both alleles acted as tran-
scriptional suppressors.27 Some functional analyses of
the ArG SNP by Sakai et al.27 were performed on the
S allele background rather than on the L allele sequence
context we consistently observed. Probably for this rea-
son, the existence of the ArG substitution was subse-
quently ignored. Recently, the G allele was reported on
the S allele background in a largely white population.
The frequency of “SG” in that study was 5/200 chro-
mosomes.18 We did not observe “SG,” although the two-
stage genotyping method we used should have detected
it. Furthermore, we sequenced 106 whites and never
observed it. Nakamura et al.8 observed it in one Japanese
individual and in none of the 148 whites they sequenced.
Therefore, we refer to the A and G alleles as LA and LG,
emphasizing that G is a sequence variation that almost
always occurs in the context of the L allele, in which it
alters AP2 binding and suppresses transcription. If the
G substitution is observed in the context of the S allele,
we suggest that it be called “SG” or “14-B” (Nakamura
et al.’s designation).
The story of the influence of HTTLPR S, LA, and LG
alleles on HTT expression is one of incremental progress
in the genetic characterization of a single neurochemical
function. In lymphoblasts, substantial variation in HTT
expression is explained by HTTLPR, but a large amount
of variation has some other origin. Although HTTLPR
predicts variation in HTT expression in the brain, there
was a similar amount of within-genotype variability.28
We predict that HTTLPR genotypes incorporating LG
will also better predict HTT expression in the brain, but,
again, there will be substantial residual variance. Assays
performed in triplicate seem to indicate that !8% of
variation in expression is attributable to measurement
error. The remaining variance may be due to differences
in expression associated with cell culture (which can be
considered another type of measurement error) and cell
line–specific factors, including other genetic loci. Al-
though an intron 2 VNTR domain has allele-dependent
enhancer activity,29,30 this locus does not independently
predict HTT expression,19 as we confirmed in the present
study.
Unrecognized LG alleles in SL and LL genotypes can
create the appearance of S allele dominance because cer-
tain of these LG-containing genotypes tend not to be high
expressing. The codominant allele action that we ob-
served is, on the other hand, consistent with the general
pattern of cis-action of promoter alleles. Probably the
main result of not scoring the LG allele is to obscure
effects of HTTLPR on phenotype, especially for phe-
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notypes (such as OCD) for which the LALA (highest
expressing) genotype is crucial and perhaps less so
for phenotypes (such as anxiety and dysphoria) for
which associations to the low-expressing S allele have
emerged.6,10,11 However, although S allele linkages to
anxiety and dysphoria are coherent with genotype effects
on brain morphometry and brain function after emo-
tional challenges, and even though these findings have
been robust in relatively small imaging data sets, the
relationship of HTT to anxiety and dysphoria is more
ambiguous.2 The contradictory findings for complex be-
havior, even in large populations, may be attributable
to a small effect size. A meta-analysis revealed that each
copy of the S allele leads to an increment of only 0.106
SD in dimensional anxiety.31 Gene-environment inter-
action is among the confounding factors. In the absence
of stress, the SS homozygous genotype does not appear
to lead to depressive symptoms in humans,11 and some-
what parallel findings have been observed in studies of
the Rhesus macaque monkey, which has an orthologous
polymorphism (rh-HTTLPR).32 In the human, changes
in brain functional activation and interregional cou-
pling predicted by the S allele were seen after cogni-
tive fear challenge but not at baseline.10 Therefore, un-
stressed populations may not so readily reveal effects of
HTTLPR on dysphoria and anxiety.
OCD is a chronic and disabling disorder characterized
by recurrent, intrusive thoughts that cause distress and
interfere with function and by repetitive behaviors or
mental acts performed in response to obsession. OCD
occurs with a frequency of ∼2% in the U.S. population
and is therefore the fourth-most-prevalent psychiatric
disorder.15,33 Often of early onset, OCD affects patients
throughout their lives, leading to diminished quality of
life for patients and families, reduced productivity, and
high health care costs. Cognitive behavioral therapy and
selective serotonin reuptake inhibitor (SSRI) drugs are
partially effective34 and have led to an interest in refining
knowledge of the etiology, which is largely unknown.
Although OCD is moderately heritable, replicated genes
for OCD are unknown, with the possible exception of
the uncommon 425Val allele in HTT. Gene discovery
could have profound implications for understanding the
neurobiology of OCD and, potentially, for treatment.
The neuroanatomical areas thought to be involved in
the pathogenesis of OCD are the frontocortical-subcor-
tical pathways, including orbitofrontal cortex, basal
ganglia, and thalamus.33 The hypothesis of a serotoner-
gic dysfunction in OCD derives largely from the clinical
observation that 5-HT reuptake–inhibiting drugs are
partially effective in treating OCD.35 Recently, Pogarell
et al.36 applied single-photon emission computed to-
mography to a small group of unmedicated patients
with OCD and control subjects and observed a 25%
increase in the specific binding of [123I]b-CIT (which ac-
cesses the serotonin transporter density) in the midbrain-
pons of the patients with OCD. These unreplicated re-
sults suggest that HTT level is increased in OCD and
are consistent with the linkage of a common high-
expressing HTT allele to OCD that we report here and
with linkage of a rare higher-functioning HTT allele,
Ile425Val, to treatment-resistant OCD and other severe
psychopathologies.15
It is interesting, and a seeming paradox, that the loss-
of-function S allele has been linked to anxiety and dys-
phoria, which, like OCD, are treated with SSRI drugs,
and that the gain-of-function LA allele is shown here to
have a role in OCD. OCD is frequently classified as an
anxiety disorder; however, anxiety has many origins. Re-
cent studies of HTTLPR in anxiety and depression in-
dicate that the S allele leads to poorer coupling of the
amygdala to regions of the brain, such as the cingulate
cortex, that modulate the amygdala and thereby mod-
ulate emotional responses.3,4 People ordinarily have the
ability to regulate emotional responses, but this regu-
lation is relatively impaired in certain individuals; in fact,
the degree of cingulate/amygdala decoupling correlated
with depression in one of these studies.4 Thus, anxiety
and dysphoria attributable to low serotonin transporter
expression appear to be a consequence of release of the
amygdala from cortical regulation and especially inhi-
bition. It has never been clear why, if the low-expressing
S allele causes anxiety and dysphoria, there would be a
positive therapeutic response to an SSRI drug, which of
course further inhibits serotonin transporter function.37
However, there is some evidence that depressed patients
with the loss-of-function S genotypes respond less well
to SSRI drugs, indicating again that serotonin trans-
porter inhibition is a key to the efficacy of SSRI drugs
in these diseases.38
OCD is not a typical anxiety disorder. In OCD, emo-
tional distress appears to be a consequence of recurrent,
intrusive thoughts. Several neurobiological models of
OCD postulate a primary role for dysfunction of the
anterior cingulate gyrus, whose hyperactivity could play
a role in abnormal conflict detection as part of an over-
active action-monitory system in OCD. Other studies
reported hypermetabolism in the cingulate gyrus,39–41
with decreased activation after treatment with SSRIs,42,43
whereas increased anterior cingulate gray matter volume
was found in patients with OCD.44–46 Therefore, the
gain-of-function HTTLPR genotype may predict hyper-
activity and more gray matter in anterior cingulate gyrus
in patients with OCD. These proposed HTT-neurobiol-
ogy relationships need to be further tested in the specific
context of OCD through combined genetic and neu-
roimaging studies.
Although the difference between the predicted
HTTLPR expression scores for patients with OCD and
controls is modest, our data support a role for HTT in
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OCD, with linkage between the disorder and high HTT
function. The HTTLPR genotype has a 1.8-fold effect
on relative risk. This is substantially less than the risk
attributable to being a first-degree relative of a patient
with OCD. Clearly, other loci are involved in the heri-
tability of OCD, and inheritance of the LALA genotype
alone is insufficient to produce OCD. We predict that
studies of other loci controlling the still-unaccounted-
for variance in HTT expression will further refine our
understanding of the neurobiology of OCD and the re-
lationship of HTT to this disease. This could even assist
in prevention and treatment of this severe disease. In
this regard, it could be critical to combine informa-
tion from genotype, clinical features of OCD (including
treatment response), and neurobiologic measures (i.e.,
frontal/amygdala connectivity) in attempts to trace the
origin of this psychiatric disease to neurobiological
determinants.
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